Imatinib: as adjuvant therapy for gastrointestinal stromal tumour (Q37794963)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 2010

edit

Language	Label	Description	Also known as
English	Imatinib: as adjuvant therapy for gastrointestinal stromal tumour	scientific article published on October 2010

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

title

Imatinib: as adjuvant therapy for gastrointestinal stromal tumour (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

main subject

imatinib

1 reference

based on heuristic

inferred from title

author

Lesley J Scott

series ordinal

2

object named as

Lesley J Scott

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

author name string

Mark Sanford

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

publication date

1 October 2010

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

published in

Drugs

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

volume

70

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

issue

15

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

page(s)

1963-1972

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

cites work

Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.2165%2F11205000-000000000-00000

retrieved

21 January 2018

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone H2AX Is a Mediator of Gastrointestinal Stromal Tumor Cell Apoptosis following Treatment with Imatinib Mesylate

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib: a review of its use in the management of gastrointestinal stromal tumours

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism and disposition of imatinib mesylate in healthy volunteers

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20883053

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.2165/11205000-000000000-00000

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

Dimensions Publication ID

1040423371

0 references

PubMed publication ID

20883053

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20883053

retrieved

23 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37794963&oldid=2200957332"